These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17881719)

  • 1. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.
    Parkinson Study Group PRECEPT Investigators
    Neurology; 2007 Oct; 69(15):1480-90. PubMed ID: 17881719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease.
    Wang LH; Johnson EM
    Neurology; 2008 Aug; 71(6):462; author reply 462-3. PubMed ID: 18678833
    [No Abstract]   [Full Text] [Related]  

  • 3. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. I can't get no satisfaction: still no neuroprotection for Parkinson disease.
    Ahlskog JE
    Neurology; 2007 Oct; 69(15):1476-7. PubMed ID: 17923609
    [No Abstract]   [Full Text] [Related]  

  • 5. Genome-wide variant by serum urate interaction in Parkinson's disease.
    Nazeri A; Roostaei T; Sadaghiani S; Chakravarty MM; Eberly S; Lang AE; Voineskos AN
    Ann Neurol; 2015 Nov; 78(5):731-41. PubMed ID: 26284320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS; Brown EM; Miller MS; Carswell S
    J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.
    Marras C; McDermott MP; Marek K; Rochon P; Naglie G; Tanner CM; Rudolph A; Shoulson I; Lang AE;
    Mov Disord; 2011 Mar; 26(4):608-13. PubMed ID: 21287602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.
    ; Schwarzschild MA; Ascherio A; Casaceli C; Curhan GC; Fitzgerald R; Kamp C; Lungu C; Macklin EA; Marek K; Mozaffarian D; Oakes D; Rudolph A; Shoulson I; Videnovic A; Scott B; Gauger L; Aldred J; Bixby M; Ciccarello J; Gunzler SA; Henchcliffe C; Brodsky M; Keith K; Hauser RA; Goetz C; LeDoux MS; Hinson V; Kumar R; Espay AJ; Jimenez-Shahed J; Hunter C; Christine C; Daley A; Leehey M; de Marcaida JA; Friedman JH; Hung A; Bwala G; Litvan I; Simon DK; Simuni T; Poon C; Schiess MC; Chou K; Park A; Bhatti D; Peterson C; Criswell SR; Rosenthal L; Durphy J; Shill HA; Mehta SH; Ahmed A; Deik AF; Fang JY; Stover N; Zhang L; Dewey RB; Gerald A; Boyd JT; Houston E; Suski V; Mosovsky S; Cloud L; Shah BB; Saint-Hilaire M; James R; Zauber SE; Reich S; Shprecher D; Pahwa R; Langhammer A; LaFaver K; LeWitt PA; Kaminski P; Goudreau J; Russell D; Houghton DJ; Laroche A; Thomas K; McGraw M; Mari Z; Serrano C; Blindauer K; Rabin M; Kurlan R; Morgan JC; Soileau M; Ainslie M; Bodis-Wollner I; Schneider RB; Waters C; Ratel AS; Beck CA; Bolger P; Callahan KF; Crotty GF; Klements D; Kostrzebski M; McMahon GM; Pothier L; Waikar SS; Lang A; Mestre T
    JAMA; 2021 Sep; 326(10):926-939. PubMed ID: 34519802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway.
    Lotharius J; Falsig J; van Beek J; Payne S; Dringen R; Brundin P; Leist M
    J Neurosci; 2005 Jul; 25(27):6329-42. PubMed ID: 16000623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD.
    Parkinson Study Group
    Neurology; 2004 Jan; 62(2):330-2. PubMed ID: 14745084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
    J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPECT-evaluation of the monoamine uptake site ligand [123I](1R)-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) in untreated patients with suspicion of Parkinson disease.
    Eising EG; Müller TT; Zander C; Kuhn W; Farahati J; Reiners C; Coenen HH
    J Investig Med; 1997 Oct; 45(8):448-52. PubMed ID: 9394097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure.
    Canesi M; Benti R; Marotta G; Cilia R; Isaias IU; Gerundini P; Pezzoli G; Antonini A
    Eur J Neurol; 2007 Mar; 14(3):297-9. PubMed ID: 17355550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of disclosure of individual imaging results in a multi-center Parkinson clinical trial.
    Jennings D; Eberly S; Oakes D; Seibyl J; Marek K; Shoulson I;
    J Parkinsons Dis; 2014; 4(4):629-38. PubMed ID: 25062961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson's Disease.
    Stephenson D; Hill D; Cedarbaum JM; Tome M; Vamvakas S; Romero K; Conrado DJ; Dexter DT; Seibyl J; Jennings D; Nicholas T; Matthews D; Xie Z; Imam S; Maguire P; Russell D; Gordon MF; Stebbins GT; Somer E; Gallagher J; Roach A; Basseches P; Grosset D; Marek K;
    J Parkinsons Dis; 2019; 9(3):553-563. PubMed ID: 31306141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).
    Parkinson Study Group
    Mov Disord; 2013 Nov; 28(13):1823-31. PubMed ID: 24123224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.
    Marras C; Lang AE; Eberly SW; Oakes D; Fahn S; Schwid SR; Hyson C; Shoulson I;
    Mov Disord; 2009 Dec; 24(16):2370-8. PubMed ID: 19908310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mixed-lineage kinases: a target for the prevention of neurodegeneration.
    Wang LH; Besirli CG; Johnson EM
    Annu Rev Pharmacol Toxicol; 2004; 44():451-74. PubMed ID: 14744254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.